Abstract | PURPOSE: In high risk gastric and gastroesophageal adenocarcinoma, adjuvant radiochemotherapy with 5-fluorouracil bolus became a standard adjuvant treatment, showing significant improvement in overall survival after surgery, although with substantial toxicity. We explored the efficacy and toxicity of a modified 5-fluorouracil continuous infusion scheme. METHODS: RESULTS: Between January 2007 and December 2013, 55 patients received a mean of 3.16 bi-weekly adjuvant infusions followed by 4.6 weeks of continuous treatment concurrent with radiotherapy and 3.72 bi-weekly infusions after radiotherapy treatment. During adjuvant treatment, grade III toxicity was mostly haematologic, while gastrointestinal and cutaneous toxicity was predominant during concurrent treatment. There were no grade IV- or treatment-related deaths during this study. Disease-free survival (DFS) was 79.2 months (56.3-102.1 months), and the 3-year survival rates were 52.7 %. CONCLUSIONS: This 5-fluorouracil infusional scheme has an excellent tolerability profile and favourable efficacy results.
|
Authors | N Martínez-Lago, M Vieito-Villar, Y Vidal-Insua, M E Padin-Iruegas, F Vazquez-Rivera, S Candamio-Folgar, R Lopez-Lopez |
Journal | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
(Clin Transl Oncol)
Vol. 17
Issue 11
Pg. 856-61
(Nov 2015)
ISSN: 1699-3055 [Electronic] Italy |
PMID | 26133519
(Publication Type: Journal Article, Observational Study)
|
Chemical References |
- Antineoplastic Agents
- Leucovorin
- Fluorouracil
|
Topics |
- Adenocarcinoma
(drug therapy, mortality)
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Chemoradiotherapy
(methods)
- Chemotherapy, Adjuvant
(adverse effects, methods)
- Disease-Free Survival
- Esophagogastric Junction
(pathology)
- Female
- Fluorouracil
(administration & dosage, adverse effects)
- Humans
- Infusions, Intravenous
- Kaplan-Meier Estimate
- Leucovorin
(therapeutic use)
- Male
- Middle Aged
- Retrospective Studies
- Stomach Neoplasms
(drug therapy, mortality)
|